Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 3/2018

Open Access 01-03-2018 | Mechanisms of Hypertension (M Weir, Section Editor)

Dysregulation of the Renin-Angiotensin System and the Vasopressinergic System Interactions in Cardiovascular Disorders

Authors: Ewa Szczepanska-Sadowska, Katarzyna Czarzasta, Agnieszka Cudnoch-Jedrzejewska

Published in: Current Hypertension Reports | Issue 3/2018

Login to get access

Abstract

Purpose of Review

In many instances, the renin-angiotensin system (RAS) and the vasopressinergic system (VPS) are jointly activated by the same stimuli and engaged in the regulation of the same processes.

Recent Findings

Angiotensin II (Ang II) and arginine vasopressin (AVP), which are the main active compounds of the RAS and the VPS, interact at several levels. Firstly, Ang II, acting on AT1 receptors (AT1R), plays a significant role in the release of AVP from vasopressinergic neurons and AVP, stimulating V1a receptors (V1aR), regulates the release of renin in the kidney. Secondly, Ang II and AVP, acting on AT1R and V1aR, respectively, exert vasoconstriction, increase cardiac contractility, stimulate the sympathoadrenal system, and elevate blood pressure. At the same time, they act antagonistically in the regulation of blood pressure by baroreflex. Thirdly, the cooperative action of Ang II acting on AT1R and AVP stimulating both V1aR and V2 receptors in the kidney is necessary for the appropriate regulation of renal blood flow and the efficient resorption of sodium and water. Furthermore, both peptides enhance the release of aldosterone and potentiate its action in the renal tubules.

Summary

In this review, we (1) point attention to the role of the cooperative action of Ang II and AVP for the regulation of blood pressure and the water-electrolyte balance under physiological conditions, (2) present the subcellular mechanisms underlying interactions of these two peptides, and (3) provide evidence that dysregulation of the cooperative action of Ang II and AVP significantly contributes to the development of disturbances in the regulation of blood pressure and the water-electrolyte balance in cardiovascular diseases.
Literature
1.
Sequeira Lopez ML, Pentz ES, Nomasa T, Smithies O, Gomez RA. Renin cells are precursors for multiple cell types that switch to the renin phenotype when homeostasis is threatened. Dev Cell. 2004;6(5):719–28.PubMedCrossRef
2.
Hobart PM, Fogliano M, O'Connor BA, Schaefer IM, Chirgwin JM. Human renin gene: structure and sequence analysis. Proc Natl Acad Sci U S A. 1984;81(16):5026–30.PubMedPubMedCentralCrossRef
3.
Morris BJ. Renin, genes, microRNAs, and renal mechanisms involved in hypertension. Hypertension. 2015;65(5):956–62.PubMedCrossRef
4.
Kuoppala A, Lindstedt KA, Saarinen J, Kovanen PT, Kokkonen JO. Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma. Am J Physiol Heart Circ Physiol. 2000;278(4):H1069–74.PubMedCrossRef
5.
Soubrier F, Wei L, Hubert C, Clauser E, Alhenc-Gelas F, Corvol P. Molecular biology of the angiotensin I converting enzyme: II. Structure-function. Gene polymorphism and clinical implications. J Hypertens. 1993;11(6):599–604.PubMedCrossRef
6.
Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87(5):E1–9.PubMedCrossRef
7.
Gomez RA, Lynch KR, Chevalier RL, Wilfong N, Everett A, Carey RM, et al. Renin and angiotensinogen gene expression in maturing rat kidney. Am J Physiol Renal Physiol. 1988;254(4):F582–7.CrossRef
8.
Ingelfinger JR, Zuo WM, Fon EA, Ellison KE, Dzau VJ. In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system. J Clin Invest. 1990;85(2):417.PubMedPubMedCentralCrossRef
9.
Leyssac PP. Changes in single nephron renin release are mediated by tubular fluid flow rate. Kidney Int. 1986;30(3):332–9.PubMedCrossRef
10.
Prieto-Carrasquero MC, Botros FT, Kobori H, Navar LG. Collecting duct renin: a major player in angiotensin II–dependent hypertension. J Am Soc Hypertens. 2009;3(2):96–104.PubMedPubMedCentralCrossRef
11.
Friis UG, Jensen BL, Sethi S, Andreasen D, Hansen PB, Skøtt O. Control of renin secretion from rat juxtaglomerular cells by cAMP-specific phosphodiesterases. Circ Res. 2002;90(9):996–1003.PubMedCrossRef
12.
Beierwaltes WH. The role of calcium in the regulation of renin secretion. Am J Physiol Renal Physiol. 2010;298(1):F1–11.PubMedCrossRef
13.
Klar J, Sigl M, Obermayer B, Schweda F, Krämer BK, Kurtz A. Calcium inhibits renin gene expression by transcriptional and posttranscriptional mechanisms. Hypertension. 2005;46(6):1340–6.PubMedCrossRef
14.
15.
Schricker K, Kurtz A. Liberators of NO exert a dual effect on renin secretion from isolated mouse renal juxtaglomerular cells. Am J Physiol Renal Physiol. 1993;265(2):F180–6.CrossRef
16.
Isaksson G, Stubbe J, Lyngs Hansen P, Jensen B, Bie P. Salt sensitivity of renin secretion, glomerular filtration rate and blood pressure in conscious Sprague-Dawley rats. Acta Physiol. 2014;210(2):446–54.CrossRef
17.
18.
• Quadri SS, Culver SA, Li C, Siragy HM. Interaction of the renin angiotensin and cox systems in the kidney. Front Biosci (Schol Ed). 2016;8:215.CrossRef
19.
20.
21.
22.
Lazartigues E, Feng Y, Lavoie JL. The two fACEs of the tissue renin-angiotensin systems: implication in cardiovascular diseases. Curr Pharm Des. 2007;13(12):1231–45.PubMedCrossRef
23.
Sawa H, Tokuchi F, Mochizuki N, Endo Y, Furuta Y, Shinohara T, et al. Expression of the angiotensinogen gene and localization of its protein in the human heart. Circulation. 1992;86(1):138–46.PubMedCrossRef
24.
Dell'Italia LJ, Meng QC, Balcells E, Wei CC, Palmer R, Hageman GR, et al. Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces. J Clin Invest. 1997;100(2):253–8.PubMedPubMedCentralCrossRef
25.
Sugiyama T, Yoshimoto T, Tsuchiya K, Gochou N, Hirono Y, Tateno T, et al. Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells. Endocrinology. 2005;146(9):3900–6.PubMedCrossRef
26.
Sadoshima J-I, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 1993;75(5):977–84.PubMedCrossRef
27.
Bader M, Ganten D. Editorial: it’s renin in the brain. Circ Res. 2002;90:8–10.PubMed
28.
29.
Tan J, Wang H, Leenen FH. Increases in brain and cardiac AT 1 receptor and ACE densities after myocardial infarct in rats. Am J Physiol Heart Circ Physiol. 2004;286(5):H1665–71.PubMedCrossRef
30.
Szczepanska-Sadowska E, Cudnoch-Jedrzejewska A, Ufnal M, Zera T. Brain and cardiovascular diseases: common neurogenic background of cardiovascular, metabolic and inflammatory diseases. J Physiol Pharmacol. 2010;61(5):509–21.PubMed
31.
Cousin C, Bracquart D, Contrepas A, Nguyen G. Potential role of the (pro) renin receptor in cardiovascular and kidney diseases. J Nephrol. 2010;23(5):508.PubMed
32.
Kubo T, Ikezawa A, Kambe T, Hagiwara Y, Fukumori R. Renin antisense injected intraventricularly decreases blood pressure in spontaneously hypertensive rats. Brain Res Bull. 2001;56(1):23–8.PubMedCrossRef
33.
Qadri F, Edling O, Wolf A, Gohlke P, Culman J, Unger T. Release of angiostensin in the paraventricular nucleus in response to hyperosmotic stimulation in conscious rats: a microdialysis study. Brain Res. 1994;637(1):45–9.PubMedCrossRef
34.
Wang JM, Slembrouck D, Tan J, Arckens L, Leenen FH, Courtoy PJ, et al. Presence of cellular renin-angiotensin system in chromaffin cells of bovine adrenal medulla. Am J Physiol Heart Circ Physiol. 2002;283(5):H1811–8.PubMedCrossRef
35.
Mulrow PJ, Franco-Saenz R. The adrenal renin-angiotensin system: a local hormonal regulator of aldosterone production. J Hypertens. 1996;14(2):173–6.PubMedCrossRef
36.
Doi Y, Atarashi K, Franco-Saenz R, Mulrow PJ. Effect of changes in sodium or potassium balance, and nephrectomy, on adrenal renin and aldosterone concentrations. Hypertension. 1984;6(2 Pt 2):I124–9.PubMedCrossRef
37.
Gupta P, Franco-Saenz R, Mulrow PJ. Locally generated angiotensin II in the adrenal gland regulates basal, corticotropin-, and potassium-stimulated aldosterone secretion. Hypertension. 1995;25(3):443–8.PubMedCrossRef
38.
Griendling KK, Murphy T, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation. 1993;87(6):1816–28.PubMedCrossRef
39.
Ishizaka N, Alexander RW, Laursen JB, Kai H, Fukui T, Oppermann M, et al. G protein-coupled receptor kinase 5 in cultured vascular smooth muscle cells and rat aorta regulation by angiotensin II and hypertension. J Biol Chem. 1997;272(51):32482–8.PubMedCrossRef
40.
Shenoy SK, Lefkowitz RJ. Angiotensin II-stimulated signaling through G proteins and β-arrestin. Sci Signal. 2005;2005(311):cm14-cm.CrossRef
41.
Griendling K, Delafontaine P, Rittenhouse S, Gimbrone M, Alexander R. Correlation of receptor sequestration with sustained diacylglycerol accumulation in angiotensin II-stimulated cultured vascular smooth muscle cells. J Biol Chem. 1987;262(30):14555–62.PubMed
42.
43.
Karamyan VT, Speth RC. Distribution of the non-AT1, non-AT2 angiotensin-binding site in the rat brain: preliminary characterization. Neuroendocrinology. 2008;88(4):256–65.PubMedCrossRef
44.
Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini D, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45(2):205–51.PubMed
45.
Shin H-M, Je H-D, Gallant C, Tao TC, Hartshorne DJ, Ito M, et al. Differential association and localization of myosin phosphatase subunits during agonist-induced signal transduction in smooth muscle. Circ Res. 2002;90(5):546–53.PubMedCrossRef
46.
• Touyz R, Schiffrin E. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol. 2004;122(4):339–52.PubMedCrossRef
47.
Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 2000;52(4):639–72.PubMed
48.
49.
Schiffrin EL, Touyz RM. From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol. 2004;287(2):H435–46.PubMedCrossRef
50.
51.
52.
53.
• Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol. 2004;6(6):499.PubMedCrossRef
54.
Lassegue B, Alexander RW, Nickenig G, Clark M, Murphy T, Griendling KK. Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation. Mol Pharmacol. 1995;48(4):601–9.PubMed
55.
•• Mitra AK, Gao L, Zucker IH. Angiotensin II-induced upregulation of AT 1 receptor expression: sequential activation of NF-κB and Elk-1 in neurons. Am J Physiol Cell Physiol. 2010;299(3):C561–9.PubMedPubMedCentralCrossRef
56.
Huwiler A, van Rossum G, Wartmann M, Pfeilschifter J. Angiotensin II stimulation of the stress-activated protein kinases in renal mesangial cells is mediated by the angiotensin AT 1 receptor subtype. Eur J Pharmacol. 1998;343(2):297–302.PubMedCrossRef
57.
Sanvitto GL, Johren O, Hauser W, Saavedra JM. Water deprivation upregulates ANG II AT1 binding and mRNA in rat subfornical organ and anterior pituitary. Am J Physiol Endocrinol Metab. 1997;273(1):E156–63.CrossRef
58.
Burnier M, Hagman M, Nussberger J, Biollaz J, Armagnac C, Brouard R, et al. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension. 1995;25(4 Pt 1):602–9.PubMedCrossRef
59.
Aguilera G, Kiss A, Luo X. Increased expression of type 1 angiotensin II receptors in the hypothalamic paraventricular nucleus following stress and glucocorticoid administration. J Neuroendocrinol. 1995;7(10):775–83.PubMedCrossRef
60.
Bhatt SR, Lokhandwala MF, Banday AA. Vascular oxidative stress upregulates angiotensin II type I receptors via mechanisms involving nuclear factor kappa B. Clin Exp Hypertens. 2014;36(6):367–73.PubMedPubMedCentralCrossRef
61.
Kang Y-M, Wang Y, Yang L-M, Elks C, Cardinale J, Yu X-J, et al. TNF-α in hypothalamic paraventricular nucleus contributes to sympathoexcitation in heart failure by modulating AT1 receptor and neurotransmitters. Tohoku J Exp Med. 2010;222(4):251–63.PubMedCrossRef
62.
Milik E, Szczepanska-Sadowska E, Cudnoch-Jedrzejewska A. Upregulation of angiotensin AT1a receptors mRNA in the heart and renal medulla after myocardial infarction in rats. J Physiol Pharmacol. 2006;57(3):375–88.PubMed
63.
Milik E, Cudnoch-Jedrzejewska A, Szczepanska-Sadowska E. Effect of chronic mild stress on AT1 receptor messenger RNA expression in the brain and kidney of rats. Psychosom Med. 2016;78(2):208–20.PubMedCrossRef
64.
Wei S-G, Yu Y, Zhang Z-H, Felder RB. Angiotensin II upregulates hypothalamic AT 1 receptor expression in rats via the mitogen-activated protein kinase pathway. Am J Physiol Heart Circ Physiol. 2009;296(5):H1425–33.PubMedPubMedCentralCrossRef
65.
Zucker IH, Schultz HD, Patel KP, Wang W, Gao L. Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure. Am J Physiol Heart Circ Physiol. 2009;297(5):H1557–66.PubMedPubMedCentralCrossRef
66.
Jesmin S, Sakuma I, Togashi H, Yoshioka M, Hattori Y, Kitabatake A, et al. Effects of endothelin receptor antagonist on expression of AT1 and AT2 receptors in the heart of SHR-SP. J Cardiovasc Pharmacol. 2004;44:S59–63.PubMedCrossRef
67.
Clark MA, Diz DI, Tallant EA. Angiotensin-(1-7) downregulates the angiotensin II type 1 receptor in vascular smooth muscle cells. Hypertension. 2001;37(4):1141–6.PubMedCrossRef
68.
Macova M, Pavel J, Saavedra JM. A peripherally administered, centrally acting angiotensin II AT 2 antagonist selectively increases brain AT 1 receptors and decreases brain tyrosine hydroxylase transcription, pituitary vasopressin and ACTH. Brain Res Bull. 2009;1250:130–40.CrossRef
69.
Van Linthout S, Spillmann F, Lorenz M, Meloni M, Jacobs F, Egorova M, et al. Vascular-protective effects of high-density lipoprotein include the downregulation of the angiotensin II type 1 receptor. Hypertension. 2009;53(4):682–7.PubMedCrossRef
70.
Feldstein JB, Sumners C, Raizada MK. Sodium increases angiotensin II receptors in neuronal cultures from brains of normotensive and hypertensive rats. Brain Res. 1986;370(2):265–72.PubMedCrossRef
71.
• Kishi T, Hirooka Y, Konno S, Ogawa K, Sunagawa K. Angiotensin II type 1 receptor-activated caspase-3 through ras/mitogen-activated protein kinase/extracellular signal-regulated kinase in the rostral ventrolateral medulla is involved in sympathoexcitation in stroke-prone spontaneously hypertensive rats. Hypertension. 2010;55(2):291–7.PubMedCrossRef
72.
Kagiyama S, Varela A, Phillips MI, Galli SM. Antisense inhibition of brain renin-angiotensin system decreased blood pressure in chronic 2-kidney, 1 clip hypertensive rats. Hypertension. 2001;37(2 Pt 2):371–5.PubMedCrossRef
73.
Huang BS, Ganten D, Leenen FH. Responses to central Na+ and ouabain are attenuated in transgenic rats deficient in brain angiotensinogen. Hypertension. 2001;37(2):683–6.PubMedCrossRef
74.
Pachori AS, Wang H, Gelband CH, Ferrario CM, Katovich MJ, Raizada MK. Inability to induce hypertension in normotensive rat expressing AT1 receptor antisense. Circ Res. 2000;86(11):1167–72.PubMedCrossRef
75.
• Cudnoch-Jedrzejewska A, Czarzasta K, Puchalska L, Dobruch J, Borowik O, Pachucki J, et al. Angiotensin converting enzyme inhibition reduces cardiovascular responses to acute stress in myocardially infarcted and chronically stressed rats. Biomed Res Int. 2014;2014 https://​doi.​org/​10.​1155/​2014/​385082.
76.
Hamaguchi R, Takemori K, Inoue T, Masuno K, Ito H. Short-term treatment of stroke-prone spontaneously hypertensive rats with an at1 receptor blocker protects against hypertensive end-organ damage by prolonged inhibition of the renin–angiotensin system. Clin Exp Pharmacol Physiol. 2008;35(10):1151–5.PubMedCrossRef
77.
Seltzer A, Bregonzio C, Armando I, Baiardi G, Saavedra JM. Oral administration of an AT 1 receptor antagonist prevents the central effects of angiotensin II in spontaneously hypertensive rats. Brain Res. 2004;1028(1):9–18.PubMedCrossRef
78.
Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000;101(13):1586–93.PubMedCrossRef
79.
Takaya T, Kawashima S, Shinohara M, Yamashita T, Toh R, Sasaki N, et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis. 2006;186(2):402–10.PubMedCrossRef
80.
Lazard D, Briend-Sutren M, Villageois P, Mattei M, Strosberg A, Nahmias C. Molecular characterization and chromosome localization of a human angiotensin II AT2 receptor gene highly expressed in fetal tissues. Receptors Channels. 1994;2(4):271–80.PubMed
81.
Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem. 1993;268(33):24539–42.PubMed
82.
Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension. 1999;33(2):613–21.PubMedCrossRef
83.
• Coleman CG, Anrather J, Iadecola C, Pickel VM. Angiotensin II type 2 receptors have a major somatodendritic distribution in vasopressin-containing neurons in the mouse hypothalamic paraventricular nucleus. Neuroscience. 2009;163(1):129–42.PubMedPubMedCentralCrossRef
84.
85.
Ozono R, Wang Z-Q, Moore AF, Inagami T, Siragy HM, Carey RM. Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension. 1997;30(5):1238–46.PubMedCrossRef
86.
Wang Z-Q, Moore AF, Ozono R, Siragy HM, Carey RM. Immunolocalization of subtype 2 angiotensin II (AT2) receptor protein in rat heart. Hypertension. 1998;32(1):78–83.PubMedCrossRef
87.
Ichiki T, Kambayashi Y, Inagami T. Multiple growth factors modulate mRNA expression of angiotensin II type-2 receptor in R3T3 cells. Circ Res. 1995;77(6):1070–6.PubMedCrossRef
88.
Kambayashi Y, Nagata K, Ichiki T, Inagami T. Insulin and insulin-like growth factors induce expression of angiotensin type-2 receptor in vascular-smooth-muscle cells. FEBS J. 1996;239(3):558–65.
89.
Siragy HM, Inagami T, Carey RM. NO and cGMP mediate angiotensin AT 2 receptor-induced renal renin inhibition in young rats. Am J Physiol Regul Integr Comp Physiol. 2007;293(4):R1461–7.PubMedCrossRef
90.
Su J-Z, Fukuda N, Jin X-Q, Lai Y-M, Suzuki R, Tahira Y, et al. Effect of AT2 receptor on expression of AT1 and TGF-β receptors in VSMCs from SHR. Hypertension. 2002;40(6):853–8.PubMedCrossRef
91.
Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K, et al. Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation. 1997;96(11):3954–62.PubMedCrossRef
92.
Kurisu S, Ozono R, Oshima T, Kambe M, Ishida T, Sugino H, et al. Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension. 2003;41(1):99–107.PubMedCrossRef
93.
Santos RA, Ferreira AJ, Simões e Silva AC. Recent advances in the angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis. Exp Physiol. 2008;93(5):519–27.PubMedCrossRef
94.
Chappell MC. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas receptor axis. Hypertension. 2007;50(4):596–9.PubMedCrossRef
95.
Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin-converting enzyme 2, angiotensin-(1–7) and Mas: new players of the renin–angiotensin system. J Endocrinol. 2013;216(2):R1–R17.PubMedCrossRef
96.
Ferreira AJ, Jacoby BA, Araújo CA, Macedo FA, Silva GA, Almeida AP, et al. The nonpeptide angiotensin-(1–7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. Am J Physiol Heart Circ Physiol. 2007;292(2):H1113–9.PubMedCrossRef
97.
Giani JF, Gironacci MM, Muñoz MC, Turyn D, Dominici FP. Angiotensin-(1–7) has a dual role on growth-promoting signalling pathways in rat heart in vivo by stimulating STAT3 and STAT5a/b phosphorylation and inhibiting angiotensin II-stimulated ERK1/2 and Rho kinase activity. Exp Physiol. 2008;93(5):570–8.PubMed
98.
Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1–7) inhibits growth of cardiac myocytes through activation of the Mas receptor. Am J Physiol Heart Circ Physiol. 2005;289(4):H1560–6.PubMedCrossRef
99.
Lara LS, Vives D, Correa JS, Cardozo FP, Marques-Fernades MF, Lopes AG, et al. PKA-mediated effect of MAS receptor in counteracting angiotensin II-stimulated renal Na+-ATPase. Arch Biochem Biophys. 2010;496(2):117–22.PubMedCrossRef
100.
Magaldi AJ, Cesar KR, de Araújo M, e Silva ACS, Santos RA. Angiotensin-(1–7) stimulates water transport in rat inner medullary collecting duct: evidence for involvement of vasopressin V2 receptors. Pflugers Arch. 2003;447(2):223–30.PubMedCrossRef
101.
Zhang J, Noble NA, Border WA, Huang Y. Infusion of angiotensin-(1–7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. Am J Physiol Renal Physiol. 2010;298(3):F579–88.PubMedCrossRef
102.
Dobruch J, Paczwa P, Lon S, Khosla MC, Szczepanska-Sadowska E. Hypotensive function of the brain angiotensin-(1-7) in Sprague Dawley and renin transgenic rats. J Physiol Pharmacol. 2003;54(3):371–81.PubMed
103.
Potts P, Horiuchi J, Coleman M, Dampney R. The cardiovascular effects of angiotensin-(1–7) in the rostral and caudal ventrolateral medulla of the rabbit. Brain Res. 2000;877(1):58–64.PubMedCrossRef
104.
Schiavone MT, Santos R, Brosnihan KB, Khosla MC, Ferrario CM. Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci. 1988;85(11):4095–8.PubMedPubMedCentralCrossRef
105.
Moriguchi A, Ferrario CM, Brosnihan KB, Ganten D, Morris M. Differential regulation of central vasopressin in transgenic rats harboring the mouse Ren-2 gene. Am J Physiol Regul Integr Comp. 1994;267(3):R786–91.CrossRef
106.
• Zhou L-M, Shi Z, Gao J, Han Y, Yuan N, Gao X-Y, et al. Angiotensin-(1–7) and angiotensin II in the rostral ventrolateral medulla modulate the cardiac sympathetic afferent reflex and sympathetic activity in rats. Pflugers Arch. 2010;459(5):681–8.PubMedCrossRef
107.
• Feng Y, Xia H, Cai Y, Halabi CM, Becker LK, Santos RA, et al. Brain-selective overexpression of human angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. Circ Res. 2010;106(2):373–82.PubMedCrossRef
108.
da Silva AQG, dos Santos RAS, Fontes MAP. Blockade of endogenous angiotensin-(1–7) in the hypothalamic paraventricular nucleus reduces renal sympathetic tone. Hypertension. 2005;46(2):341–8.PubMedCrossRef
109.
110.
Pinheiro SV, Ferreira AJ, Kitten GT, Da Silveira KD, Da Silva DA, Santos SH, et al. Genetic deletion of the angiotensin-(1–7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. Kidney Int. 2009;75(11):1184–93.PubMedCrossRef
111.
Yugandhar VG, Clark MA. Angiotensin III: a physiological relevant peptide of the renin angiotensin system. Peptides. 2013;46:26–32.PubMedCrossRef
112.
Yang R, Walther T, Gembardt F, Smolders I, Vanderheyden P, Albiston AL, et al. Renal vasoconstrictor and pressor responses to angiotensin IV in mice are AT1a-receptor mediated. J Hypertens. 2010;28(3):487–94.PubMedCrossRef
113.
Fung M-L, Lam S-Y, Wong T-P, Tjong Y-W, Leung P-S. Carotid body AT4 receptor expression and its upregulation in chronic hypoxia. Open Cardiovasc Med J. 2007;1:1.PubMedPubMedCentralCrossRef
114.
Touyz RM. The role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep. 2003;5(2):155–64.PubMedCrossRef
115.
Gohla A, Schultz G, Offermanns S. Role for G12/G13 in agonist-induced vascular smooth muscle cell contraction. Circ Res. 2000;87(3):221–7.PubMedCrossRef
116.
Inagami T. Molecular biology and signaling of angiotensin receptors: an overview. J Am Soc Nephrol. 1999;10(Suppl 11):S2–7.PubMed
117.
De Mello WC. Intracellular angiotensin II increases the total potassium current and the resting potential of arterial myocytes from vascular resistance vessels of the rat. Physiological and pathological implications. J Am Soc Hypertens. 2013;7(3):192–7.PubMedCrossRef
118.
119.
Tummala PE, Chen X-L, Sundell CL, Laursen JB, Hammes CP, Alexander RW, et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature. Circulation. 1999;100(11):1223–9.PubMedCrossRef
120.
Gosgnach W, Challah M, Coulet F, Michel J-B, Battle T. Shear stress induces angiotensin converting enzyme expression in cultured smooth muscle cells: possible involvement of bFGF. Cardiovasc Res. 2000;45(2):486–92.PubMedCrossRef
121.
122.
Peters J, Farrenkopf R, Clausmeyer S, Zimmer J, Kantachuvesiri S, Sharp MG, et al. Functional significance of prorenin internalization in the rat heart. Circ Res. 2002;90(10):1135–41.PubMedCrossRef
123.
124.
Rogers TB, Lokuta AJ. Angiotensin II signal transduction pathways in the cardiovascular system. Trends Cardiovasc Med. 1994;4(3):110–6.PubMedCrossRef
125.
• García-Hoz C, Sánchez-Fernández G, García-Escudero R, Fernández-Velasco M, Palacios-García J, Ruiz-Meana M, et al. Protein kinase C (PKC) ζ-mediated Gαq stimulation of ERK5 protein pathway in cardiomyocytes and cardiac fibroblasts. J Biol Chem. 2012;287(10):7792–802.PubMedPubMedCentralCrossRef
126.
Thibault G, Lacombe M-J, Schnapp LM, Lacasse A, Bouzeghrane F, Lapalme G. Upregulation of α 8 β 1-integrin in cardiac fibroblast by angiotensin II and transforming growth factor-β1. Am J Physiol Cell Physiol. 2001;281(5):C1457–67.PubMedCrossRef
127.
Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, Hannan RD. Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res. 2002;90(2):135–42.PubMedCrossRef
128.
129.
Banerjee I, Yekkala K, Borg TK, Baudino TA. Dynamic interactions between myocytes, fibroblasts, and extracellular matrix. Ann N Y Acad Sci. 2006;1080(1):76–84.PubMedCrossRef
130.
• Kakishita M, Nakamura K, Asanuma M, Morita H, Saito H, Kusano K, et al. Direct evidence for increased hydroxyl radicals in angiotensin II-induced cardiac hypertrophy through angiotensin II type 1a receptor. J Cardiovasc Pharmacol. 2003;42:S67–70.PubMedCrossRef
131.
Everett AD, Tufro-McReddie A, Fisher A, Gomez RA. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression. Hypertension. 1994;23(5):587–92.PubMedCrossRef
132.
133.
Miguel-Carrasco JL, Monserrat MT, Mate A, Vázquez CM. Comparative effects of captopril and l-carnitine on blood pressure and antioxidant enzyme gene expression in the heart of spontaneously hypertensive rats. Eur J Pharmacol. 2010;632(1):65–72.PubMedCrossRef
134.
Tsutsumi Y, Matsubara H, Ohkubo N, Mori Y, Nozawa Y, Murasawa S, et al. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res. 1998;83(10):1035–46.PubMedCrossRef
135.
Smookler HH, Severs WB, Kinnard WJ, Buckley JP. Centrally mediated cardiovascular effects of angiotensin II. J Pharmacol Exp Ther. 1966;153(3):485–94.PubMed
136.
Buckley JP. Actions of angiotensin on the central nervous system. Fed Proc. 1972;31(4):1332–7.PubMed
137.
• Lon S, Szczepanska-Sadowska E, Szczypaczewska M. Evidence that centrally released arginine vasopressin is involved in central pressor action of angiotensin II. Am J Physiol Heart Circ Physiol. 1996;270(1):H167–73.CrossRef
138.
Schölkens B, Jung W, Rascher W, Schömig A, Ganten D. Brain angiotensin II stimulates release of pituitary hormones, plasma catecholamines and increases blood pressure in dogs. Clin Sci (Lond). 1980;59:53s–6s.CrossRef
139.
• Allen AM, O’Callaghan E, Chen D, Bassi J. Central neural regulation of cardiovascular function by angiotensin: a focus on the rostral ventrolateral medulla. Neuroendocrinology. 2009;89(4):361–9.PubMedCrossRef
140.
Chen C-Y, Huang W-C. Pressor and renal effects of intracerebroventricularly administered angiotensins II and III in rats. Kidney Blood Press Res. 2000;23(2):95–105.PubMedCrossRef
141.
Ferguson AV, Washburn DL. Angiotensin II: a peptidergic neurotransmitter in central autonomic pathways. Prog Neurobiol. 1998;54(2):169–92.PubMedCrossRef
142.
•• Nasimi A, Kafami M. Vasopressin and sympathetic system mediate the cardiovascular effects of the angiotensin II in the bed nucleus of the stria terminalis in rat. Neurosci Res. 2016;108:34–9.PubMedCrossRef
143.
Dampney RA, Tan PS, Sheriff MJ, Fontes MA, Horiuchi J. Cardiovascular effects of angiotensin II in the rostral ventrolateral medulla: the push-pull hypothesis. Curr Hypertens Rep. 2007;9(3):222–7.PubMedCrossRef
144.
145.
• Szczepanska-Sadowska E, Paczwa P, Lon S, Ganten D. Increased pressor function of central vasopressinergic system in hypertensive renin transgenic rats. J Hypertens. 1998;16(10):1505–14.PubMedCrossRef
146.
147.
DiBona GF. Central sympathoexcitatory actions of angiotensin II: role of type 1 angiotensin II receptors. J Am Soc Nephrol. 1999;10(Suppl 11):S90–4.PubMed
148.
Sagara Y, Hirooka Y, Nozoe M, Ito K, Kimura Y, Sunagawa K. Pressor response induced by central angiotensin II is mediated by activation of Rho/Rho-kinase pathway via AT1 receptors. J Hypertens. 2007;25(2):399–406.PubMedCrossRef
149.
Chen Q, Pan H-L. Signaling mechanisms of angiotensin II-induced attenuation of GABAergic input to hypothalamic presympathetic neurons. J Neurophysiol. 2007;97(5):3279–87.PubMedCrossRef
150.
Zhu G-Q, Patel KP, Zucker IH, Wang W. Microinjection of ANG II into paraventricular nucleus enhances cardiac sympathetic afferent reflex in rats. Am J Physiol Heart Circ Physiol. 2002;282(6):H2039–45.PubMedCrossRef
151.
Gao J, Zhang H, Le KD, Chao J, Gao L. Activation of central angiotensin type 2 receptors suppresses norepinephrine excretion and blood pressure in conscious rats. Am J Hypertens. 2011;24(6):724–30.PubMedPubMedCentralCrossRef
152.
153.
Gao L, Wang W, Wang W, Li H, Sumners C, Zucker IH. Effects of angiotensin type 2 receptor overexpression in the rostral ventrolateral medulla on blood pressure and urine excretion in normal rats. Hypertension. 2008;51(2):521–7.PubMedCrossRef
154.
He X, Zhao M, Bi X, Sun L, Yu X, Zhao M, et al. Novel strategies and underlying protective mechanisms of modulation of vagal activity in cardiovascular diseases. Br J Pharmacol. 2015;172(23):5489–500.PubMedPubMedCentralCrossRef
155.
156.
Oliveira-Sales EB, Colombari DS, Davisson RL, Kasparov S, Hirata AE, Campos RR, et al. Kidney-induced hypertension depends on superoxide signaling in the rostral ventrolateral medulla. Hypertension. 2010;56(2):290–6.PubMedCrossRef
157.
Bunag RD, Page IH, McCubbin JW. Neural stimulation of release of renin. Circ Res. 1966;19(4):851–8.PubMedCrossRef
158.
Liu J-L, Murakami H, Sanderford M, Bishop VS, Zucker IH. ANG II and baroreflex function in rabbits with CHF and lesions of the area postrema. Am J Physiol Heart Circ Physiol. 1999;277(1):H342–50.CrossRef
159.
Llewellyn TL, Sharma NM, Zheng H, Patel KP. Effects of exercise training on SFO-mediated sympathoexcitation during chronic heart failure. Am J Physiol Heart Circ Physiol. 2014;306(1):H121–31.PubMedCrossRef
160.
Strömberg C, Tsutsumi K, Viswanathan M, Saavedra JM. Angiotensin II AT1 receptors in rat superior cervical ganglia: characterization and stimulation of phosphoinositide hydrolysis. Eur J Pharmacol. 1991;208(4):331–6.PubMedCrossRef
161.
Dendorfer A, Thornagel A, Raasch W, Grisk O, Tempel K, Dominiak P. Angiotensin II induces catecholamine release by direct ganglionic excitation. Hypertension. 2002;40(3):348–54.PubMedCrossRef
162.
FARR WC, GRUPP G. Ganglionic stimulation: mechanism of the positive inotropic and chronotropic effects of angiotensin. J Pharmacol Exp Ther. 1971;177(1):48–55.PubMed
163.
Castren E, Kurihara M, Gutkind JS, Saavedra JM. Specific angiotensin II binding sites in the rat stellate and superior cervical ganglia. Brain Res. 1987;422(2):347–51.PubMedCrossRef
164.
Ma X, Chapleau MW, Whiteis CA, Abboud FM, Bielefeldt K. Angiotensin selectively activates a subpopulation of postganglionic sympathetic neurons in mice. Cir Res. 2001;88(8):787–93.CrossRef
165.
Shapiro MS, Wollmuth LP, Hille B. Angiotensin II inhibits calcium and M current channels in rat sympathetic neurons via G proteins. Neuron. 1994;12(6):1319–29.PubMedCrossRef
166.
Acosta E, Mendoza V, Castro E, Cruzblanca H. Modulation of a delayed-rectifier K+ current by angiotensin II in rat sympathetic neurons. J Neurophysiol. 2007;98(1):79–85.PubMedCrossRef
167.
Allen AM, Lewis SJ, Verberne AJ, Mendelsohn FA. Angiotensin receptors and the vagal system. Clin Exp Hypertens A. 1988;10(6):1239–49.PubMed
168.
Du XJ, Cox HS, Dart AM, Esler MD. Depression of efferent parasympathetic control of heart rate in rats with myocardial infarction: effect of losartan. J Cardiovasc Pharmacol. 1998;31(6):937–44.PubMedCrossRef
169.
Flapan AD, Nolan J, Neilson JM, Ewing DJ. Effect of captopril on cardiac parasympathetic activity in chronic cardiac failure secondary to coronary artery disease. Am J Cardiol. 1992;69(5):532–5.PubMedCrossRef
170.
Osterziel KJ, Dietz R. Improvement of vagal tone by ACE inhibition: a mechanism of cardioprotection in patients with mild-to-moderate heart failure. J Cardiovasc Pharmacol. 1996;27:25–30.CrossRef
171.
• Allen AM, Moeller I, Jenkins TA, Zhuo J, Aldred GP, Chai SY, et al. Angiotensin receptors in the nervous system. Brain Res Bull. 1998;47(1):17–28.PubMedCrossRef
172.
Barron KW, Trapani AJ, Gordon FJ, Brody MJ. Baroreceptor denervation profoundly enhances cardiovascular responses to central angiotensin II. Am J Physiol Heart Circ Physiol. 1989;257(1):H314–23.CrossRef
173.
Brooks VL, Ell KR, Wright RM. Pressure-independent baroreflex resetting produced by chronic infusion of angiotensin II in rabbits. Am J Physiol Heart Circ Physiol. 1993;265(4):H1275–82.CrossRef
174.
• Head G, Saigusa T, Mayorov D. Angiotensin and baroreflex control of the circulation. Braz J Med Biol Res. 2002;35(9):1047–59.PubMedCrossRef
175.
Saigusa T, Iriki M, Arita J. Brain angiotensin II tonically modulates sympathetic baroreflex in rabbit ventrolateral medulla. Am J Physiol Heart Circ Physiol. 1996;271(3):H1015–21.CrossRef
176.
Polson JW, Dampney RA, Boscan P, Pickering AE, Paton JF. Differential baroreflex control of sympathetic drive by angiotensin II in the nucleus tractus solitarii. Am J Physiol Regul Integr Comp Physiol. 2007;293(5):R1954–60.PubMedCrossRef
177.
Tan PS, Killinger S, Horiuchi J, Dampney RA. Baroreceptor reflex modulation by circulating angiotensin II is mediated by AT 1 receptors in the nucleus tractus solitarius. Am J Physiol Regul Integr Comp Physiol. 2007;293(6):R2267–78.PubMedCrossRef
178.
Palma-Rigo K, Bassi JK, Nguyen-Huu T-P, Jackson KL, Davern PJ, Chen D, et al. Angiotensin 1A receptors transfected into caudal ventrolateral medulla inhibit baroreflex gain and stress responses. Cardiovasc Res. 2012;96(2):330–9.PubMedCrossRef
179.
Wang W-Z, Gao L, Wang H-J, Zucker IH, Wang W. Interaction between cardiac sympathetic afferent reflex and chemoreflex is mediated by the NTS AT 1 receptors in heart failure. Am J Physiol Heart Circ Physiol. 2008;295(3):H1216–26.PubMedPubMedCentralCrossRef
180.
Murakami H, Liu J-L, Zucker IH. Angiotensin II enhances baroreflex control of sympathetic outflow in heart failure. Hypertension. 1997;29(2):564–9.PubMedCrossRef
181.
Zhang W, Huang BS, Leenen FH. Brain renin-angiotensin system and sympathetic hyperactivity in rats after myocardial infarction. Am J Physiol Heart Circ Physiol. 1999;276(5):H1608–15.CrossRef
182.
183.
184.
185.
Yamazato M, Ferreira AJ, Yamazato Y, Diez-Freire C, Yuan L, Gillies R, et al. Gene transfer of angiotensin-converting enzyme 2 in the nucleus tractus solitarius improves baroreceptor heart rate reflex in spontaneously hypertensive rats. J Renin-Angiotensin-Aldosterone Syst. 2011;12(4):456–61.PubMedPubMedCentralCrossRef
186.
187.
Bacal K, Kunze D. Dual effects of angiotensin II on calcium currents in neonatal rat nodose neurons. J Neurosci. 1994;14(11):7159–67.PubMedCrossRef
188.
Takahashi K, Hiraishi K, Hirose T, Kato I, Yamamoto H, Shoji I, et al. Expression of (pro) renin receptor in the human brain and pituitary, and co-localisation with arginine vasopressin and oxytocin in the hypothalamus. J Neuroendocrinol. 2010;22(5):453–9.PubMedCrossRef
189.
Fyhrquist F, Eriksson L, Wallenius M. Plasma vasopressin in conscious goats after cerebroventricular infusions of angiotensins, sodium chloride, and fructose. Endocrinology. 1979;104(4):1091–5.PubMedCrossRef
190.
Zini S, Fournie-Zaluski M-C, Chauvel E, Roques BP, Corvol P, Llorens-Cortes C. Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Proc Natl Acad Sci. 1996;93(21):11968–73.PubMedPubMedCentralCrossRef
191.
Foster RH, MacFarlane CH, Bustamante MO. Recent progress in understanding aldosterone secretion. Gen Pharmacol. 1997;28(5):647–51.PubMedCrossRef
192.
Rautureau Y, Paradis P, Schiffrin EL. Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells. Steroids. 2011;76(9):834–9.PubMed
193.
Schiffrin EL, Gutkowska J, Genest J. Effect of angiotensin II and deoxycorticosterone infusion on vascular angiotensin II receptors in rats. Am J Physiol Heart Circ Physiol. 1984;246(4):H608–14.CrossRef
194.
Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40(4):504–10.PubMedCrossRef
195.
Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii T, Higaki J, et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol. 2006;26(4):917–21.PubMedCrossRef
196.
Coghlan J, Considine P, Denton D, Fei D, Leksell L, McKinley M, et al. Sodium appetite in sheep induced by cerebral ventricular infusion of angiotensin: comparison with sodium deficiency. Science. 1981;214(4517):195–7.PubMedCrossRef
197.
Fitzsimons J. Angiotensin, thirst, and sodium appetite. Physiol Res. 1998;78(3):583–686.
198.
Morris MJ, Wilson WL, Starbuck EM, Fitts DA. Forebrain circumventricular organs mediate salt appetite induced by intravenous angiotensin II in rats. Brain Res. 2002;949(1):42–50.PubMedCrossRef
199.
Shade RE, Blair-West JR, Carey KD, Madden LJ, Weisinger RS, Denton DA. Synergy between angiotensin and aldosterone in evoking sodium appetite in baboons. Am J Physiol Regul Integr Comp Physiol. 2002;283(5):R1070–8.PubMedCrossRef
200.
Abrao Saad W, Antonio De Arruda Camargo L, Sergio Cerri P, Simoes S, Abrao Saad W, Garcia G, et al. Influence of arginine vasopressin receptors and angiotensin receptor subtypes on the water intake and arterial blood pressure induced by vasopressin injected into the lateral septal area of the rat. Auton Neurosci. 2004;111(1):66–70. https://​doi.​org/​10.​1016/​j.​autneu.​2003.​08.​013.PubMedCrossRef
201.
de Arruda Camargo LA, Saad WA, Cerri PS. Effects of V1 and angiotensin receptor subtypes of the paraventricular nucleus on the water intake induced by vasopressin injected into the lateral septal area. Brain Res Bull. 2003;61(5):481–7.PubMedCrossRef
202.
McKinley M, Cairns M, Denton D, Egan G, Mathai M, Uschakov A, et al. Physiological and pathophysiological influences on thirst. Physiol Behav. 2004;81(5):795–803.PubMedCrossRef
203.
Szczepanska-Sadowska E. Hormonal inputs to thirst. In: Ramsay DJ, Booth D, editors. Thirst: physiological and psychological aspects. London: Springer London; 1991. p. 110–30.CrossRef
204.
Wright JW, Sullivan MJ, Quirk WS, Batt CM, Harding JW. Heightened blood pressure and drinking responsiveness to intracerebroventricularly applied angiotensins in the spontaneously hypertensive rat. Brain Res. 1987;420(2):289–94.PubMedCrossRef
205.
Miyata N, Park F, Li XF, Cowley AW. Distribution of angiotensin AT 1 and AT 2 receptor subtypes in the rat kidney. Am J Physiol Renal Physiol. 1999;277(3):F437–46.CrossRef
206.
207.
Oliverio MI, Best CF, Smithies O, Coffman TM. Regulation of sodium balance and blood pressure by the AT1A receptor for angiotensin II. Hypertension. 2000;35(2):550–4.PubMedCrossRef
208.
Oliverio MI, Delnomdedieu M, Best CF, Li P, Morris M, Callahan MF, et al. Abnormal water metabolism in mice lacking the type 1A receptor for ANG II. Am J Physiol Renal Physiol. 2000;278(1):F75–82.PubMedCrossRef
209.
Casare FAM, Thieme K, Costa-Pessoa JM, Rossoni LV, Couto GK, Fernandes FB, et al. Renovascular remodeling and renal injury after extended angiotensin II infusion. Am J Physiol Regul Integr Comp Physiol. 2016;310(11):F1295–307.CrossRef
210.
Kihara M, Umemura S, Sumida Y, Yokoyama N, Yabana M, Nyui N, et al. Genetic deficiency of angiotensinogen produces an impaired urine concentrating ability in mice. Kidney Int. 1998;53(3):548–55.PubMedCrossRef
211.
212.
• Szczepanska-Sadowska E, Zera T, Sosnowski P, Cudnoch-Jedrzejewska A, Puszko A, Misicka A. Vasopressin and related peptides; potential value in diagnosis, prognosis and treatment of clinical disorders. Curr Drug Metab. 2017;18(4):306–45.PubMedCrossRef
213.
Buijs R, Swaab D. Immuno-electron microscopical demonstration of vasopressin and oxytocin synapses in the limbic system of the rat. Cell Tissue Res. 1979;204(3):355–65.PubMedCrossRef
214.
van Leeuwen F, Caffé R. Vasopressin-immunoreactive cell bodies in the bed nucleus of the stria terminalis of the rat. Cell Tissue Res. 1983;228(3):525–34.PubMedCrossRef
215.
Wacker DW, Tobin VA, Noack J, Bishop VR, Duszkiewicz AJ, Engelmann M et al. inventors; Expression of early growth response protein 1 in vasopressin neurones of the rat anterior olfactory nucleus following social odour exposure patent 1469–7793. 2010.
216.
Ginsberg SD, Hof PR, Young WG, Morrison JH. Noradrenergic innervation of vasopressin-and oxytocin-containing neurons in the hypothalamic paraventricular nucleus of the macaque monkey: quantitative analysis using double-label immunohistochemistry and confocal laser microscopy. J Comp Neurol. 1994;341(4):476–91.PubMedCrossRef
217.
Sawchenko PE, Swanson LW. Immunohistochemical identification of neurons in the paraventricular nucleus of the hypothalamus that project to the medulla or to the spinal cord in the rat. J Comp Neurol. 1982;205(3):260–72.PubMedCrossRef
218.
• Hallbeck M, Hermanson O, Blomqvist A. Distribution of preprovasopressin mRNA in the rat central nervous system. J Comp Neurol. 1999;411(2):181–200.PubMedCrossRef
219.
• Hallbeck M, Blomqvist A. Spinal cord-projecting vasopressinergic neurons in the rat paraventricular hypothalamus. J Comp Neurol. 1999;411(2):201–11.PubMedCrossRef
220.
Ludwig M, Stern J. Multiple signalling modalities mediated by dendritic exocytosis of oxytocin and vasopressin. Phil Trans R Soc B. 2015;370(1672):20140182.PubMedPubMedCentralCrossRef
221.
Hupf H, Grimm D, Riegger GA, Schunkert H. Evidence for a vasopressin system in the rat heart. Circ Res. 1999;84(3):365–70.PubMedCrossRef
222.
Ravid R, Oosterbaan H, Hansen B, Swaab D. Localisation of oxytocin, vasopressin and parts of precursors in the human neonatal adrenal. Histochem Cell Biol. 1986;84(4):401–7.
223.
Yibchok-anun S, Abu-Basha EA, Yao C-Y, Panichkriangkrai W, Hsu WH. The role of arginine vasopressin in diabetes-associated increase in glucagon secretion. Regul Pept. 2004;122(3):157–62.PubMedCrossRef
224.
225.
Janas S, Seghers F, Schakman O, Alsady M, Deen P, Vriens J, et al. TRPV4 is associated with central rather than nephrogenic osmoregulation. Pflugers Arch. 2016;468(9):1595–607.PubMedCrossRef
226.
Dawson CA, Jhamandas JH, Krukoff TL. Activation by systemic angiotensin II of neurochemically identified neurons in rat hypothalamic paraventricular nucleus. J Neuroendocrinol. 1998;10(6):453–9.PubMedCrossRef
227.
Kageyama K, Kumata Y, Akimoto K, Takayasu S, Tamasawa N, Suda T. Ghrelin stimulates corticotropin-releasing factor and vasopressin gene expression in rat hypothalamic 4B cells. Stress. 2011;14(5):520–9.PubMedCrossRef
228.
Sladek CD, Kapoor JR. Neurotransmitter/neuropeptide interactions in the regulation of neurohypophyseal hormone release. Exp Neurol. 2001;171(2):200–9.PubMedCrossRef
229.
230.
231.
Tobin VA, Bull PM, Arunachalam S, O'Carroll A-M, Ueta Y, Ludwig M. The effects of apelin on the electrical activity of hypothalamic magnocellular vasopressin and oxytocin neurons and somatodendritic peptide release. Endocrinology. 2008;149(12):6136–45.PubMedPubMedCentralCrossRef
232.
Zhang L, Tong M, Xiao M, Li L, Ding J. Nitric oxide mediates feedback inhibition in angiotensin II-induced upregulation of vasopressin mRNA. Peptides. 2009;30(5):913–7.PubMedCrossRef
233.
234.
Haam J, Popescu IR, Morton LA, Halmos KC, Teruyama R, Ueta Y, et al. GABA is excitatory in adult vasopressinergic neuroendocrine cells. J Neurosci. 2012;32(2):572–82.PubMedPubMedCentralCrossRef
235.
Kim Y-B, Kim YS, Kim WB, Shen F-Y, Lee SW, Chung HJ, et al. GABAergic excitation of vasopressin neurons novelty and significance. Circ Res. 2013;113(12):1296–307.PubMedCrossRef
236.
Jorgensen H, Knigge U, Kjaer A, Warberg J. Serotonergic involvement in stress-induced vasopressin and oxytocin secretion. Eur J Endocrinol. 2002;147(6):815–24.PubMedCrossRef
237.
Haque M, Wilson R, Sharma K, Mills N, Teruyama R. Localisation of 11β-hydroxysteroid dehydrogenase type 2 in mineralocorticoid receptor expressing magnocellular neurosecretory neurones of the rat supraoptic and paraventricular nuclei. J Neuroendocrinol. 2015;27(11):835–49.PubMedPubMedCentralCrossRef
238.
• Pietranera L, Saravia F, Roig P, Lima A, De Nicola AF. Mineralocorticoid treatment upregulates the hypothalamic vasopressinergic system of spontaneously hypertensive rats. Neuroendocrinology. 2004;80(2):100–10.PubMedCrossRef
239.
Amin MS, Wang H-W, Reza E, Whitman SC, Tuana BS, Leenen FH. Distribution of epithelial sodium channels and mineralocorticoid receptors in cardiovascular regulatory centers in rat brain. Am J Physiol Regul Integr Comp Physiol. 2005;289(6):R1787–97.PubMedCrossRef
240.
Teruyama R, Sakuraba M, Wilson LL, Wandrey NE, Armstrong WE. Epithelial Na+ sodium channels in magnocellular cells of the rat supraoptic and paraventricular nuclei. Am J Physiol Endocrinol Metab. 2012;302(3):E273–85.PubMedCrossRef
241.
Abel A, Wittau N, Wieland T, Schultz G, Kalkbrenner F. Cell cycle-dependent coupling of the vasopressin V1a receptor to different G proteins. J Biol Chem. 2000;275(42):32543–51.PubMedCrossRef
242.
Schoneberg T, Kostenis E, Liu J, Gudermann T, Wess J. Molecular aspects of vasopressin receptor function. Adv Exp Med Biol. 1998;449:347–58.PubMedCrossRef
243.
• Phillips PA, Kelly JM, Abrahams JM, Grzonka Z, Paxinos G, Mendelsohn FA, et al. Vasopressin receptors in rat brain and kidney: studies using a radio-iodinated V1 receptor antagonist. J Hypertens. 1988;6(4):S550–3.CrossRef
244.
• Góźdź A, Szczepańska-Sadowska E, Maśliński W, Kumosa M, Szczepańska K, Dobruch J. Differential expression of vasopressin V1a and V1b receptors mRNA in the brain of renin transgenic TGR (mRen2) 27 and Sprague–Dawley rats. Brain Res Bull. 2003;59(5):399–403.PubMedCrossRef
245.
• Young L, Toloczko D, Insel R. Localization of vasopressin (V~ 1~ a) receptor binding and mRNA in the rhesus monkey brain. J Neuroendocrinol. 1999;11:291–8.PubMedCrossRef
246.
Moriya T, Kayano T, Kitamura N, Hosaka YZ, Asano A, Forostyak O, et al. Vasopressin-induced intracellular Ca 2+ concentration responses in non-neuronal cells of the rat dorsal root ganglion. Brain Res. 2012;1483:1–12.PubMedCrossRef
247.
Arpin-Bott MP, Waltisperger E, Freund-Mercier MJ, Stoeckel ME. Historadioautographic localization, pharmacology and ontogeny of V(1a) vasopressin binding sites in the rat kidney. Nephron. 1999;83(1):74–84.PubMedCrossRef
248.
Koshimizu T-A, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev. 2012;92(4):1813–64.PubMedCrossRef
249.
• Park F, Mattson DL, Skelton MM, Cowley AW. Localization of the vasopressin V1a and V2 receptors within the renal cortical and medullary circulation. Am J Physiol Regul Integr Comp Physiol. 1997;273(1):R243–51.CrossRef
250.
• Gozdz A, Szczepanska-Sadowska E, Szczepanska K, Maslinski W, Luszczyk B. Vasopressin V1a, V1b and V2 receptors mRNA in the kidney and heart of the renin transgenic TGR(mRen2)27 and Sprague Dawley rats. J Physiol Pharmacol. 2002;53(3):349–57.PubMed
251.
Hernando F, Schoots O, Lolait SJ, Burbach JPH. Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin. Endocrinology. 2001;142(4):1659–68.PubMedCrossRef
252.
Roper JA, O'Carroll A, Young W III, Lolait S. The vasopressin Avpr1b receptor: molecular and pharmacological studies. Stress. 2011;14(1):98–115.PubMedCrossRef
253.
• Zhang J, Sato M, Duzic E, Kubalak SW, Lanier SM, Webb JG. Adenylyl cyclase isoforms and vasopressin enhancement of agonist-stimulated cAMP in vascular smooth muscle cells. Am J Physiol-Heart Circ Physiol. 1997;273(2):H971–80.CrossRef
254.
• Henderson KK, Byron KL. Vasopressin-induced vasoconstriction: two concentration-dependent signaling pathways. J Appl Physiol. 2007;102(4):1402–9.PubMedPubMedCentralCrossRef
255.
• Brueggemann LI, Moran CJ, Barakat JA, Yeh JZ, Cribbs LL, Byron KL. Vasopressin stimulates action potential firing by protein kinase C-dependent inhibition of KCNQ5 in A7r5 rat aortic smooth muscle cells. Am J Physiol Heart Circ Physiol. 2007;292(3):H1352–H63.PubMedCrossRef
256.
257.
• Nishiwaki-Yasuda K, Suzuki A, Kakita A, Sekiguchi S, Asano S, Nishii K, et al. Vasopressin stimulates Na-dependent phosphate transport and calcification in rat aortic smooth muscle cells. Endocr J. 2007;54(1):103–12.PubMedCrossRef
258.
• Jackiewicz E, Szczepanska-Sadowska E, Dobruch J. Altered expression of angiotensin AT1a and vasopressin V1a receptors and nitric oxide synthase mRNA in the brain of rats with renovascular hypertension. J Physiol Pharmacol. 2004;55(4):725–37.PubMed
259.
•• Milik E, Szczepanska-Sadowska E, Dobruch J, Cudnoch-Jedrzejewska A, Maslinski W. Altered expression of V1a receptors mRNA in the brain and kidney after myocardial infarction and chronic stress. Neuropeptides. 2014;48(5):257–66.PubMedCrossRef
260.
• Mutig K, Paliege A, Kahl T, Jöns T, Müller-Esterl W, Bachmann S. Vasopressin V 2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL. Am J Physiol Renal Physiol. 2007;293(4):F1166–77.PubMedCrossRef
261.
• Hayashi M, Sasaki S, Tsuganezawa H, Monkawa T, Kitajima W, Konishi K, et al. Role of vasopressin V2 receptor in acute regulation of aquaporin-2. Kidney Blood Press Res. 1996;19(1):32–7.PubMedCrossRef
262.
263.
264.
Szalai B, Hoffmann P, Prokop S, Erdélyi L, Várnai P, Hunyady L. Improved methodical approach for quantitative BRET analysis of G protein coupled receptor dimerization. PLoS One. 2014;9(10):e109503.PubMedPubMedCentralCrossRef
265.
• Gonzalez CB, Herrera VL, Ruiz-Opazo N. Renal immunocytochemical distribution and pharmacological properties of the dual angiotensin II/AVP receptor. Hypertension. 1997;29(4):957–61.PubMedCrossRef
266.
• Cowley AW Jr, Monos E, Guyton AC. Interaction of vasopressin and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog. Circ Res. 1974;34(4):505–14.PubMedCrossRef
267.
• Szczepańska-Sadowska E. Hemodynamic effects of moderate increase of the plasma vasopressin level in conscious dogs. Pflugers Arch. 1973;338(4):313–22.PubMedCrossRef
268.
• Motawei K, Pyner S, Ranson RN, Kamel M, Coote JH. Terminals of paraventricular spinal neurones are closely associated with adrenal medullary sympathetic preganglionic neurones: immunocytochemical evidence for vasopressin as a possible neurotransmitter in this pathway. Exp Brain Res. 1999;126(1):68–76.PubMedCrossRef
269.
• Altura BM, Altura BT. Actions of vasopressin, oxytocin, and synthetic analogs on vascular smooth muscle. Fed Proc. 1984;43(1):80–6.PubMed
270.
• Hidaka T, Tsuneyoshi I, Boyle WA 3rd, Onomoto M, Yonetani S, Hamasaki J, et al. Marked synergism between vasopressin and angiotensin II in a human isolated artery. Crit Care Med. 2005;33(11):2613–20.PubMedCrossRef
271.
• Kaplan-Albuquerque N, Garat C, Van Putten V, Nemenoff RA. Regulation of SM22α expression by arginine vasopressin and PDGF-BB in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2003;285(4):H1444–52.PubMedCrossRef
272.
• Nishihashi T, Trandafir CC, Wang A, Ji X, Kurahashi K. Enhanced reactivity to vasopressin in rat basilar arteries during vasospasm after subarachnoid hemorrhage. Eur J Pharmacol. 2005;513(1):93–100.PubMedCrossRef
273.
• Friedman SM. Additive effects of aldosterone with vasopressin or angiotensin. Hypertension. 1984;6(2 Pt 1):242–8.PubMed
274.
• Leung E, Johnston CI, Woodcock EA. Stimulation of phosphatidylinositol metabolism in the heart. Clin Exp Pharmacol Physiol. 1986;13(4):359–63.PubMedCrossRef
275.
• Gutkowska J, Miszkurka M, Danalache B, Gassanov N, Wang D, Jankowski M. Functional arginine vasopressin system in early heart maturation. Am J Physiol Heart Circ Physiol. 2007;293(4):H2262–70.PubMedCrossRef
276.
• Weig H-J, Laugwitz K-L, Moretti A, Kronsbein K, Städele C, Brüning S, et al. Enhanced cardiac contractility after gene transfer of V2 vasopressin receptors in vivo by ultrasound-guided injection or transcoronary delivery. Circulation. 2000;101(13):1578–85.PubMedCrossRef
277.
• Pelletier J-S, LaBossiere J, Dicken B, Gill RS, Sergi C, Tahbaz N, et al. Low-dose vasopressin improves cardiac function in newborn piglets with acute hypoxia-reoxygenation. Shock. 2013;40(4):320–6.PubMedCrossRef
278.
• Hiroyama M, Wang S, Aoyagi T, Oikawa R, Sanbe A, Takeo S, et al. Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V 1A receptor in neonatal mice. Eur J Pharmacol. 2007;559(2):89–97.PubMedCrossRef
279.
• Mayr VD, Wenzel V, Wagner-Berger HG, Stadlbauer KH, Cavus E, Raab H, et al. Arginine vasopressin during sinus rhythm: effects on haemodynamic variables, left anterior descending coronary artery cross sectional area and cardiac index, before and after inhibition of NO-synthase, in pigs. Resuscitation. 2007;74(2):366–71.PubMedCrossRef
280.
• Fan Y-H, Zhao L-Y, Zheng Q-S, Dong H, Wang H-C. Yang X-d. Arginine vasopressin increases iNOS–NO system activity in cardiac fibroblasts through NF-κB activation and its relation with myocardial fibrosis. Life Sci. 2007;81(4):327–35.PubMedCrossRef
281.
• Niu X, Xue Y, Li X, He Y, Zhao X, Xu M, et al. Effects of angiotensin-(1-7) on the proliferation and collagen synthesis of arginine vasopressin–stimulated rat cardiac fibroblasts: role of mas receptor-calcineurin-NF-κB signaling pathway. J Cardiovasc Pharmacol. 2014;64(6):536–42.PubMedCrossRef
282.
•• Ebert TJ, Cowley AW, Skelton M. Vasopressin reduces cardiac function and augments cardiopulmonary baroreflex resistance increases in man. J Clin Invest. 1986;77(4):1136–42.PubMedPubMedCentralCrossRef
283.
• Goldsmith SR. The role of vasopressin in congestive heart failure. Cleve Clin J Med. 2006;73(Suppl 3):S19–23.PubMedCrossRef
284.
• Chen X, Lu G, Tang K, Li Q, Gao X. The secretion patterns and roles of cardiac and circulating arginine vasopressin during the development of heart failure. Neuropeptides. 2015;51:63–73.PubMedCrossRef
285.
286.
287.
• Iversen BM, Arendshorst WJ. ANG II and vasopressin stimulate calcium entry in dispersed smooth muscle cells of preglomerular arterioles. Am J Physiol Renal Physiol. 1998;274(3):F498–508.CrossRef
288.
• Okuda T, Yamashita N, Kurokawa K. Angiotensin II and vasopressin stimulate calcium-activated chloride conductance in rat mesangial cells. J Clin Invest. 1986;78(6):1443.PubMedPubMedCentralCrossRef
289.
• Weihprecht H, Lorenz JN, Briggs JP, Schnermann J. Vasoconstrictor effect of angiotensin and vasopressin in isolated rabbit afferent arterioles. Am J Physiol Renal Physiol. 1991;261(2):F273–82.CrossRef
290.
• Ganz M, Boyarsky G, Boron W, Sterzel R. Effects of angiotensin II and vasopressin on intracellular pH of glomerular mesangial cells. Am J Physiol Renal Physiol. 1988;254(6):F787–94.CrossRef
291.
• Ganz M, Pekar S, Perfetto M, Sterzel R. Arginine vasopressin promotes growth of rat glomerular mesangial cells in culture. Am J Physiol Renal Physiol. 1988;255(5):F898–906.CrossRef
292.
• Evans RG, Bergstrom G, Lawrence AJ. Effects of the vasopressin V1 agonist [Phe2,Ile3,Orn8] vasopressin on regional kidney perfusion and renal excretory function in anesthetized rabbits. J Cardiovasc Pharmacol. 1998;32(4):571–81.PubMedCrossRef
293.
• Franchini KG, Cowley A. Renal cortical and medullary blood flow responses during water restriction: role of vasopressin. Am J Physiol Regul Integr Comp Physiol. 1996;270(6):R1257–64.CrossRef
294.
• Szczepanska-Sadowska E, Stepniakowski K, Skelton M, Cowley A. Prolonged stimulation of intrarenal V1 vasopressin receptors results in sustained hypertension. Am J Physiol Regul Integr Comp Physiol. 1994;267(5):R1217–25.CrossRef
295.
• Goncharuk VD, Buijs RM, Jhamandas JH, Swaab DF. Vasopressin (VP) and neuropeptide FF (NPFF) systems in the normal and hypertensive human brainstem. J Comp Neurol. 2011;519(1):93–124.PubMedCrossRef
296.
• Martin S, Malkinson T, Veale W, Pittman Q. The action of centrally administered arginine vasopressin on blood pressure in the conscious rabbit. Brain Res. 1985;348(1):137–45.PubMedCrossRef
297.
• Noszczyk B, Łon S, Szczepańska-Sadowska E. Central cardiovascular effects of AVP and AVP analogs with V 1, V 2 and ‘V 3’agonistic or anatagonistic properties in conscious dog. Brain Res. 1993;610(1):115–26.PubMedCrossRef
298.
•• Kc P, Balan KV, Tjoe SS, Martin RJ, LaManna JC, Haxhiu MA, et al. Increased vasopressin transmission from the paraventricular nucleus to the rostral medulla augments cardiorespiratory outflow in chronic intermittent hypoxia-conditioned rats. J Physiol. 2010;588(4):725–40.PubMedPubMedCentralCrossRef
299.
• Jansen A, Wessendorf M, Loewy A. Transneuronal labeling of CNS neuropeptide and monoamine neurons after pseudorabies virus injections into the stellate ganglion. Brain Res. 1995;683(1):1–24.PubMedCrossRef
300.
• Hanley MR, Benton HP, Lightman SL, Todd K, Bone EA, Fretten P, et al. A vasopressin-like peptide in the mammalian sympathetic nervous system. Nature. 1984;309(5965):258–61.PubMedCrossRef
301.
• Horn AM, Lightman SL. Vasopressin-stimulated turnover of phosphatidylinositol in the decentralised superior cervical ganglion of the rat. Brain Res. 1988;455(1):18–23.PubMedCrossRef
302.
• Gilbey MP, Coote JH, Fleetwood-Walker S, Peterson DF. The influence of the paraventriculo-spinal pathway, and oxytocin and vasopressin on sympathetic preganglionic neurones. Brain Res. 1982;251(2):283–90.PubMedCrossRef
303.
• Yamaguchi-Shima N, Okada S, Shimizu T, Usui D, Nakamura K, Lu L, et al. Adrenal adrenaline-and noradrenaline-containing cells and celiac sympathetic ganglia are differentially controlled by centrally administered corticotropin-releasing factor and arginine–vasopressin in rats. Eur J Pharmacol. 2007;564(1):94–102.PubMedCrossRef
304.
• Patel K, Schmid P. Vasopressin inhibits sympathetic ganglionic transmission but potentiates sympathetic neuroeffector responses in hindlimb vasculature of rabbits. J Pharmacol Exp Ther. 1988;245(3):779–85.PubMed
305.
• Brizzee BL, Walker BR. Vasopressinergic augmentation of cardiac baroreceptor reflex in conscious rats. Am J Phys. 1990;258(4 Pt 2):R860–8.
306.
• Cowley AW Jr, Liard JF. Vasopressin and arterial pressure regulation. Special lecture. Hypertension. 1988;11(2 Pt 2):I25–32.PubMedCrossRef
307.
• Guo G, Schmid PG, Abboud FM. Sites at which vasopressin facilitates baroreflex inhibition of lumbar sympathetic nerve activity. Am J Physiol Heart Circ Physiol. 1986;251(3):H644–55.CrossRef
308.
• Cox BF, Hay M, Bishop VS. Neurons in area postrema mediate vasopressin-induced enhancement of the baroreflex. Am J Phys. 1990;258(6 Pt 2):H1943–6.
309.
• Hegarty AA, Felder RB. Vasopressin and V1-receptor antagonists modulate the activity of NTS neurons receiving baroreceptor input. Am J Physiol Regul Integr Comp Physiol. 1997;273(1):R143–52.CrossRef
310.
• Oikawa R, Nasa Y, Ishii R, Kuwaki T, Tanoue A, Tsujimoto G, et al. Vasopressin V1A receptor enhances baroreflex via the central component of the reflex arc. Eur J Pharmacol. 2007;558(1):144–50.PubMedCrossRef
311.
• Balasubramanian L, Sham JS, Yip K-P. Calcium signaling in vasopressin-induced aquaporin-2 trafficking. Pflugers Arch. 2008;456(4):747–54.PubMedCrossRef
312.
• Nielsen S, Frøkiær J, Marples D, Kwon T-H, Agre P, Knepper MA. Aquaporins in the kidney: from molecules to medicine. Physiol Rev. 2002;82(1):205–44.PubMedCrossRef
313.
• Michlig S, Mercier A, Doucet A, Schild L, Horisberger J-D, Rossier BC, et al. ERK1/2 controls Na, K-ATPase activity and transepithelial sodium transport in the principal cell of the cortical collecting duct of the mouse kidney. J Biol Chem. 2004;279(49):51002–12.PubMedCrossRef
314.
• Mordasini D, Bustamante M, Rousselot M, Martin P-Y, Hasler U, Féraille E. Stimulation of Na+ transport by AVP is independent of PKA phosphorylation of the Na-K-ATPase in collecting duct principal cells. Am J Physiol Renal Physiol. 2005;289(5):F1031–9.PubMedCrossRef
315.
316.
• Kato A, Klein JD, Zhang C, Sands JM. Angiotensin II increases vasopressin-stimulated facilitated urea permeability in rat terminal IMCDs. Am J Physiol Renal Physiol. 2000;279(5):F835–40.PubMedCrossRef
317.
• Nicco C, Wittner M, DiStefano A, Jounier S, Bankir L, Bouby N. Chronic exposure to vasopressin upregulates ENaC and sodium transport in the rat renal collecting duct and lung. Hypertension. 2001;38(5):1143–9.PubMedCrossRef
318.
319.
320.
321.
• Ahmed AB, George BC, Gonzalez-Auvert C, Dingman JF. Increased plasma arginine vasopressin in clinical adrenocortical insufficiency and its inhibition by glucosteroids. J Clin Invest. 1967;46(1):111.PubMedPubMedCentralCrossRef
322.
• Bugaj V, Pochynyuk O, Stockand JD. Activation of the epithelial Na+ channel in the collecting duct by vasopressin contributes to water reabsorption. Am J Physiol Renal Physiol. 2009;297(5):F1411–8.PubMedPubMedCentralCrossRef
323.
324.
• Djelidi S, Beggah A, Courtois-Coutry N, Fay M, Cluzeaud F, Viengchareun S, et al. Basolateral translocation by vasopressin of the aldosterone-induced pool of latent Na-K-ATPases is accompanied by alpha1 subunit dephosphorylation: study in a new aldosterone-sensitive rat cortical collecting duct cell line. J Am Soc Nephrol. 2001;12(9):1805–18.PubMed
325.
• Perlewitz A, Nafz B, Skalweit A, Fähling M, Persson PB, Thiele B-J. Aldosterone and vasopressin affect α-and γ-ENaC mRNA translation. Nucleic Acids Res. 2010;38(17):5746–60.PubMedPubMedCentralCrossRef
326.
327.
• Izumi Y, Hori K, Nakayama Y, Kimura M, Hasuike Y, Nanami M, et al. Aldosterone requires vasopressin V1a receptors on intercalated cells to mediate acid-base homeostasis. J Am Soc Nephrol. 2011;22(4):673–80.PubMedPubMedCentralCrossRef
328.
• Saxena A, Bachelor M, Park YH, Carreno FR, Nedungadi TP, Cunningham JT. Angiotensin II induces membrane trafficking of natively expressed transient receptor potential vanilloid type 4 channels in hypothalamic 4B cells. Am J Physiol Regul Integr Comp Physiol. 2014;307(8):R945–55.PubMedPubMedCentralCrossRef
329.
330.
• Aoyagi T, Koshimizu T-A, Tanoue A. Vasopressin regulation of blood pressure and volume: findings from V1a receptor-deficient mice. Kidney Int. 2009;76(10):1035–9.PubMedCrossRef
331.
332.
• Cudnoch-Jedrzejewska A, Szczepanska-Sadowska E, Dobruch J, Puchalska L, Ufnal M, Kowalewski S, et al. Differential sensitisation to central cardiovascular effects of angiotensin II in rats with a myocardial infarct: relevance to stress and interaction with vasopressin. Stress. 2008;11(4):290–301. https://​doi.​org/​10.​1080/​1025389070179444​5.PubMedCrossRef
333.
• Ito S, Komatsu K, Tsukamoto K, Kanmatsuse K, Sved AF. Ventrolateral medulla AT1 receptors support blood pressure in hypertensive rats. Hypertension. 2002;40(4):552–9.PubMedCrossRef
334.
• Szczepanska-Sadowska E. Role of neuropeptides in central control of cardiovascular responses to stress. J Physiol Pharmacol. 2008;59(Suppl 8):61–89.PubMed
335.
336.
• Gebke E, Müller A, Jurzak M, Gerstberger R. Angiotensin II-induced calcium signalling in neurons and astrocytes of rat circumventricular organs. Neuroscience. 1998;85(2):509–20.PubMedCrossRef
337.
• Jeulin A, Nicolaidis S. Evidence for vasopressin V1 receptors of rostrodiencephalic neurons: iontophoretic studies in the in vivo rat. Responses to oxytocin and to angiotensin. Brain Res Bull. 1988;20(6):817–23.PubMedCrossRef
338.
• Consolim-Colombo FM, Hay M, Smith TC, Elizondo-Fournier M, Bishop VS. Subcellular mechanisms of angiotensin II and arginine vasopressin activation of area postrema neurons. Am J Physiol Regul Integr Comp Physiol. 1996;271(1):R34–41.CrossRef
339.
• Hay M, Edwards G, Lindsley K, Murphy S, Sharma R, Bhalla R, et al. Increases in cytosolic Ca 2+ in rat area postrema/mNTS neurons produced by angiotensin II and arginine-vasopressin. Neurosci Lett. 1993;151(2):121–5.PubMedCrossRef
340.
• Hasser EM, Bishop VS, Hay M. Interactions between vasopressin and baroreflex control of the sympathetic nervous system. Clin Exp Pharmacol Physiol. 1997;24(1):102–8.PubMedCrossRef
341.
• Walker J, Jennings DB. During acute hypercapnia vasopressin inhibits an angiotensin drive to ventilation in conscious dogs. J Appl Physiol. 1995;79(3):786–94.PubMedCrossRef
342.
• Gonzalez AA, Cifuentes-Araneda F, Ibaceta-Gonzalez C, Gonzalez-Vergara A, Zamora L, Henriquez R, et al. Vasopressin/V2 receptor stimulates renin synthesis in the collecting duct. Am J Physiol Renal Physiol. 2016;310(4):F284–93.PubMedCrossRef
343.
• Wong NL, Tsui JK. Angiotensin II upregulates the expression of vasopressin V2 mRNA in the inner medullary collecting duct of the rat. Metabolism. 2003;52(3):290–5.PubMedCrossRef
344.
• Torp M, Brønd L, Hadrup N, Nielsen J, Prætorius J, Nielsen S, et al. Losartan decreases vasopressin-mediated cAMP accumulation in the thick ascending limb of the loop of Henle in rats with congestive heart failure. Acta Physiol. 2007;190(4):339–50.CrossRef
345.
• Lee Y-J, Song I-K, Jang K-J, Nielsen J, Frøkiær J, Nielsen S, et al. Increased AQP2 targeting in primary cultured IMCD cells in response to angiotensin II through AT 1 receptor. Am J Physiol Renal Physiol. 2007;292(1):F340–50.PubMedCrossRef
346.
• Wang W, Li C, Summer S, Falk S, Schrier RW. Interaction between vasopressin and angiotensin II in vivo and in vitro: effect on aquaporins and urine concentration. Am J Physiol Renal Physiol. 2010;299(3):F577–84.PubMedPubMedCentralCrossRef
347.
• Kwon T-H, Nielsen J, Knepper MA, Frøkiær J, Nielsen S. Angiotensin II AT 1 receptor blockade decreases vasopressin-induced water reabsorption and AQP2 levels in NaCl-restricted rats. Am J Physiol Renal Physiol. 2005;288(4):F673–84.PubMedCrossRef
Metadata
Title
Dysregulation of the Renin-Angiotensin System and the Vasopressinergic System Interactions in Cardiovascular Disorders
Authors
Ewa Szczepanska-Sadowska
Katarzyna Czarzasta
Agnieszka Cudnoch-Jedrzejewska
Publication date
01-03-2018
Publisher
Springer US
Published in
Current Hypertension Reports / Issue 3/2018
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-018-0823-9

Other articles of this Issue 3/2018

Current Hypertension Reports 3/2018 Go to the issue

Hypertension and the Kidney (RM Carey, Section Editor)

Control of Energy Expenditure by AgRP Neurons of the Arcuate Nucleus: Neurocircuitry, Signaling Pathways, and Angiotensin

Mechanisms of Hypertension (M Weir, Section Editor)

Percutaneous Creation of a Central Iliac Arteriovenous Anastomosis for the Treatment of Arterial Hypertension

Hypertension and Emergency Medicine (T Rainer and P Levy, Section Editors)

Novel Biomarkers to Detect Target Organ Damage in Acute Hypertension

Hypertension and Obesity (E Reisin, Section Editor)

Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome

Blood Pressure Monitoring and Management (J Cockcroft, Section Editor)

Cerebral Haemodynamics: Effects of Systemic Arterial Pulsatile Function and Hypertension

Secondary Hypertension: Nervous System Mechanisms (M Wyss, Section Editor)

Renal Nerve Stimulation as Procedural End Point for Renal Sympathetic Denervation

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits